California State Teachers Retirement System Purchases 12,838,761 Shares of Charles River Laboratories International, Inc. $CRL

California State Teachers Retirement System grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 22,535.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,895,733 shares of the medical research company’s stock after buying an additional 12,838,761 shares during the period. California State Teachers Retirement System owned approximately 0.27% of Charles River Laboratories International worth $2,924,623,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Continuum Advisory LLC acquired a new stake in Charles River Laboratories International during the 2nd quarter worth $30,000. Los Angeles Capital Management LLC acquired a new position in Charles River Laboratories International in the fourth quarter valued at about $42,000. Sfam LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at approximately $43,000. Geneos Wealth Management Inc. increased its position in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth $46,000. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Evercore reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Royal Bank Of Canada boosted their price target on Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Robert W. Baird set a $291.00 price objective on Charles River Laboratories International in a research report on Thursday, August 6th. Finally, Barclays reiterated an “overweight” rating and set a $300.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Eleven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $259.44.

Charles River Laboratories International Trading Down 2.0%

Shares of NYSE:CRL opened at $272.68 on Friday. The company’s 50-day moving average price is $259.22 and its two-hundred day moving average price is $205.07. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $303.30. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The stock has a market capitalization of $13.02 billion, a PE ratio of -56.22, a price-to-earnings-growth ratio of 2.73 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.33 EPS for the current fiscal year.

Insider Activity

In other news, Director James Foster sold 75,000 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This represents a 70.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the transaction, the chief executive officer directly owned 36,013 shares of the company’s stock, valued at $10,080,038.70. This represents a 15.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 165,990 shares of company stock valued at $42,606,388. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.